Siddhartha Yadav, Associate Professor of Oncology and Consultant Medical Oncologist at the Mayo Clinic, shared a post on LinkedIn about a recent article he and colleagues authored:
“Some publications are special – not just for their scientific impact, but for what they represent personally.
In our latest work in Clinical Cancer Research, we uncover key differences between pancreatic cancers associated with germline ATM pathogenic variants and sporadic cases, using whole-genome, exome, and transcriptome sequencing, along with CODEX multiplex immunophenotyping.
We found that the absence of p53 alterations and HRD signatures, combined with CDKN2A enrichment in gATM-associated PDAC, points to unique tumor biology and tumorigenesis.
This study is especially meaningful to me – it began back in 2019 during my fellowship, supported by an American Society of Clinical Oncology (ASCO) Young Investigator Award. While it took time to bring to completion, it laid the foundation for my understanding of tumor biology and shaped my ongoing work in precision oncology and therapeutic vulnerability mapping using genomic tools.”
Title: Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM
Authors: Siddhartha Yadav, Riyue Bao, Rondell P. Graham, Chunling Hu, Steven N. Hart, Jie Na, Nicholas Boddicker, Rohan D. Gnanaolivu, James Smadbeck, Li Ding, Daniel D. Billadeau, Aaron T. Mayer, Shounak Majumder, Paulo Cilas Morais Lyra, Adrian V. Lee, Alvaro N. Monteiro, Jose C. Villasboas, Robert McWilliams, Fergus J. Couch
Read the Full Article in Clinical Cancer Research.
More posts featuring Siddhartha Yadav on OncoDaily.